Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet pa...
OPKO Health, Inc. is a diversified healthcare c...
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to ...
Rexahn Pharmaceuticals is a clinical stage biop...
Sutro Biopharma, located in South San Francisco, is a clinical-stage drug discover...
Sutro Biopharma, located in South San Francisco...
We are a global medical technology company focused on the design, development and ...
We are a global medical technology company focu...
Ultrasonic Medical Mapping, Inc., (UMM) is headquartered in Bethesda, MD. The comp...
Ultrasonic Medical Mapping, Inc., (UMM) is head...
Stop the root cause of snoring by going directly after the tongue. ZYPPAH is the o...
Stop the root cause of snoring by going directl...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...
Join the National Investor Network and get the latest information with your interests in mind.